X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs TORRENT PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS TORRENT PHARMA IPCA LABS/
TORRENT PHARMA
 
P/E (TTM) x 25.9 61.4 42.2% View Chart
P/BV x 4.4 5.8 75.7% View Chart
Dividend Yield % 0.1 0.9 12.1%  

Financials

 IPCA LABS   TORRENT PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
TORRENT PHARMA
Mar-18
IPCA LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6951,550 44.9%   
Low Rs4001,144 35.0%   
Sales per share (Unadj.) Rs260.2354.7 73.4%  
Earnings per share (Unadj.) Rs19.040.1 47.3%  
Cash flow per share (Unadj.) Rs33.164.2 51.5%  
Dividends per share (Unadj.) Rs1.0014.00 7.1%  
Dividend yield (eoy) %0.21.0 17.6%  
Book value per share (Unadj.) Rs213.0273.1 78.0%  
Shares outstanding (eoy) m126.20169.22 74.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.13.8 55.4%   
Avg P/E ratio x28.933.6 85.9%  
P/CF ratio (eoy) x16.621.0 79.0%  
Price / Book Value ratio x2.64.9 52.1%  
Dividend payout %5.334.9 15.1%   
Avg Mkt Cap Rs m69,120227,897 30.3%   
No. of employees `00013.314.7 90.2%   
Total wages/salary Rs m7,35911,353 64.8%   
Avg. sales/employee Rs Th2,477.44,083.0 60.7%   
Avg. wages/employee Rs Th555.2772.3 71.9%   
Avg. net profit/employee Rs Th180.6461.3 39.2%   
INCOME DATA
Net Sales Rs m32,83660,021 54.7%  
Other income Rs m4182,988 14.0%   
Total revenues Rs m33,25463,009 52.8%   
Gross profit Rs m4,50513,493 33.4%  
Depreciation Rs m1,7774,086 43.5%   
Interest Rs m2403,085 7.8%   
Profit before tax Rs m2,9059,310 31.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5112,529 20.2%   
Profit after tax Rs m2,3946,781 35.3%  
Gross profit margin %13.722.5 61.0%  
Effective tax rate %17.627.2 64.8%   
Net profit margin %7.311.3 64.5%  
BALANCE SHEET DATA
Current assets Rs m19,45552,623 37.0%   
Current liabilities Rs m10,07652,022 19.4%   
Net working cap to sales %28.61.0 2,850.2%  
Current ratio x1.91.0 190.9%  
Inventory Days Days98120 81.9%  
Debtors Days Days6776 87.8%  
Net fixed assets Rs m20,26085,016 23.8%   
Share capital Rs m252846 29.8%   
"Free" reserves Rs m26,63345,376 58.7%   
Net worth Rs m26,88646,222 58.2%   
Long term debt Rs m2,34041,115 5.7%   
Total assets Rs m41,173142,432 28.9%  
Interest coverage x13.14.0 325.9%   
Debt to equity ratio x0.10.9 9.8%  
Sales to assets ratio x0.80.4 189.3%   
Return on assets %6.46.9 92.4%  
Return on equity %8.914.7 60.7%  
Return on capital %10.814.2 75.8%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64214,580 107.3%   
Fx outflow Rs m4,8843,600 135.7%   
Net fx Rs m10,75910,980 98.0%   
CASH FLOW
From Operations Rs m3,4118,942 38.2%  
From Investments Rs m-1,354-47,070 2.9%  
From Financial Activity Rs m-1,30434,174 -3.8%  
Net Cashflow Rs m753-3,655 -20.6%  

Share Holding

Indian Promoters % 45.9 71.5 64.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 7.0 162.4%  
FIIs % 25.3 12.6 200.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.8 197.7%  
Shareholders   36,892 26,511 139.2%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   GLENMARK PHARMA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  UNICHEM LAB  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; FMCG and Banking Stocks Gain(12:30 pm)

Stock markets in India are presently trading higher. The BSE Sensex is trading up by 104 points and the NSE Nifty is trading up by 32 points.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jul 17, 2019 01:51 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS